About Us

Since 2016, Weill Cornell Medicine (New York) and the Gustave Roussy Cancer Campus (Paris) have joined forces to organize an annual conference that provides a forum for education, discussion, and networking among investigators interested in developing safe and effective RT-IT combinations (ImmunoRad).

Contact Info

Email
christine.corinus

Phone
+33 (0) 1 42 11 53 22

  Gustave Roussy Cancer Campus,
Research Department
Pièce 65 - B2M

 

あなたが使う言語を選んでください

Poster session

ImmunoRad Paris 2025

Eric Deutsch

Gustave Roussy Cancer Campus, Paris, France

 

Eric Deutsch, MD, PhD is currently full-professor in radiation oncology at Paris-Saclay University, Director of the Inserm UMR1030 molecular radiotherapy and innovative therapeutics research unit, and Chair of the department of radiation oncology at Gustave Roussy Cancer Campus, Villejuif, France.

In 2003, he gained a PhD degree in the fundamental basis of oncogenesis at Paris-Saclay University and completed his training with a post-doctoral fellowship in the Department of Radiation Oncology at the University of Pennsylvania, Philadelphia, United States. Under his leadership, Prof. Deutsch manages more than 100 people (clinic and research) and is well versed in the field of translational research and early clinical trials.

He has developed a novel research axis in the department related to the personalization of radiotherapy and immunotherapy treatments using artificial intelligence tools, in collaboration with TPC and Ecole CentraleSupelec. He has investigated several innovative drug products as principal investigator in first-in-human clinical studies, including several immunomodulators in combination with radiotherapy.

As medical director of the Gustave Roussy transfer office, he is well versed into transfer, valorization and contracting aspects of research. Prof. Deutsch has (co-)authored >260 publications in international peer-reviewed journals, with >15.000 citations and a Google Scholar H–Index of 57. His research interests focuses on cell death mechanisms, HPV-related tumors and tumor-stroma interplay, with a strong immunological component.